Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Sinovac Biotech Ltd.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

CanSino Biologics Inc.

Sinovac Biotech is a Chinese biopharmaceutical company that develops and manufactures vaccines. Known for its COVID-19 vaccine, CoronaVac, the company also develops vaccines for other diseases like influenza and hepatitis B.

Metric
Company Name	Sinovac Biotech Ltd.	CanSino Biologics Inc.
Symbol	SVA	6.18K
MSH ID	COM:SINOVAC	COM:CANSINOTECH
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Drug Manufacturers - Specialty & Generic
Country	CN	CN
Stage
Employee Count	1.96K	1.49K
Website	sinovacbio.com	cansinotech.com
LinkedIn		cansino-biotechnology-inc.
Founders

Metric
Market Cap	464.94M	833.96M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	448.27M	49.12M
Revenue (LTM)
Revenue (NTM)
Gross Profit	266.75M	-61.04M
EBITDA	-401.98M	-203.86M
Operating Income	-546.72M	-236.92M
Net Income	-99.92M	-203.94M
EPS	-1	-0.83
Diluted EPS	-1	-0.83
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.58	0.14
Operating Profit Margin	-1.24	-0.86
EBITDA Margin	-0.90	-4.15
Net Profit Margin	-0.22	-1.42
Return on Equity	-0.01	-0.16
Return on Assets	-0.01	-0.11
Return on Capital Employed	-0.04	-0.08

COM:SINOVAC

Sinovac Biotech

Last Close

6.47

14/11 21:00

Market Cap

464.94M

Beta: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	5.65
P/B Ratio	0.07
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.10	20.35
EV Multiple	-1.37	-3.00

Metric
Days Sales Outstanding	149.03	485.87
Days Payables Outstanding	10.57	170.20
Days Inventory Outstanding	270.97	251.49
Operating Cycle	637.97	815.83
Cash Conversion Cycle	604.47	770.86
Asset Turnover	0.03	0.07

Metric
Operating Cash Flow	106.02M	-124.92M
Free Cash Flow	-39.67M	-208.89M
Cash Flow to Debt	0.42	-0.12
Operating Cash Flow/Sales	0.27	-0.43
Free Cash Flow Yield	-2.53	-0.25

Metric
Cash & Equivalents	1.28B	388.10M
Accounts Receivable	82.15M	36.58M
Inventory	139.87M	48.53M
Goodwill
Debt to Capitalization	0.03	0.34
Debt to Assets	0.01	0.21
Current Ratio	11.11	2.24
Quick Ratio	10.17	2.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.10
R&D to Revenue	0.30	1.04
SG&A to Revenue		0.34